Crossmark

Leveraging fine-mapping and multipopulation training data to improve cross-population polygenic risk scores

Crossref DOI link: https://doi.org/10.1038/s41588-022-01036-9

Published Online: 2022-04-07

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Weissbrod, Omer https://orcid.org/0000-0001-9860-0626
Kanai, Masahiro https://orcid.org/0000-0001-5165-4408
Shi, Huwenbo https://orcid.org/0000-0001-9886-877X
Gazal, Steven

Peyrot, Wouter J. https://orcid.org/0000-0001-7954-8383
Khera, Amit V.

Okada, Yukinori https://orcid.org/0000-0002-0311-8472
,

Matsuda, Koichi

Yamanashi, Yuji

Furukawa, Yoichi

Morisaki, Takayuki

Murakami, Yoshinori

Kamatani, Yoichiro

Muto, Kaori

Nagai, Akiko

Obara, Wataru

Yamaji, Ken

Takahashi, Kazuhisa

Asai, Satoshi

Takahashi, Yasuo

Suzuki, Takao

Sinozaki, Nobuaki

Yamaguchi, Hiroki

Minami, Shiro

Murayama, Shigeo

Yoshimori, Kozo

Nagayama, Satoshi

Obata, Daisuke

Higashiyama, Masahiko

Masumoto, Akihide

Koretsune, Yukihiro

Martin, Alicia R. https://orcid.org/0000-0003-0241-3522
Finucane, Hilary K. https://orcid.org/0000-0003-3864-9828
Price, Alkes L. https://orcid.org/0000-0002-2971-7975
Funding

Funding for this research was provided by:

Heiwa Nakajima Foundation

Masason Foundation

NWO Veni grant

U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (1K08HG010155, 1U01HG011719)

IBM Research

MEXT | Japan Society for the Promotion of Science (19H01021, 20K21834)

Japan Agency for Medical Research and Development (JP21km0405211, JP21ek0109413, JP21ek0410075, JP21gm4010006)

MEXT | Japan Science and Technology Agency (JPMJMS2021, JPMJMS2024)

U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K99/R00MH117229)

P. A. Messerschmidt og Hustrus Fond

Eric and Wendy Schmidt

U.S. Department of Health & Human Services | National Institutes of Health (R37 MH107649, R01 HG006399, U01 HG012009, U01 HG009379)
License Information

Text and Data Mining valid from 2022-04-01

Version of Record valid from 2022-04-01
More Information

Article History

Received: 10 January 2021

Accepted: 25 February 2022

First Online: 7 April 2022

Competing interests

: O.W. is an employee and holds equity in Eleven Therapeutics. H.S. is an employee of Genentech and holds stock in Roche. A.V.K. is an employee and holds equity in Verve Therapeutics, and has served as a scientific advisor to Sanofi, Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Foresite Labs and Columbia University (NIH); A.V.K. received speaking fees from Illumina, MedGenome, Amgen and the Novartis Institute for Biomedical Research, and also received a sponsored research agreement from IBM Research. All other authors declare no competing interests.

Document is current

Any future updates will be listed below